CAS |
No.75738-58-8 |
中文名称 |
盐酸头孢甲肟 |
英文名称 |
Cefmenoxime Hydrochloride |
别名 |
Cefmenoxime hemihydrochloride;SCE-1365 hemihydrochloride |
分子式 |
C32H34N18O10S6·HCl |
分子量 |
1059.58 |
溶解性 |
Soluble in DMSO ≥5mg/mL |
纯度 |
≥98% |
外观(性状) |
Light yellow to yellow Solid |
储存条件 |
Powder:2-8℃,2 years;Insolvent(母液):-20℃,6 months;-80℃,1 year |
运输条件 |
冷藏运输 |
EC |
EINECS 278-299-4 |
MDL |
MFCD01750403 |
SMILES |
OC(C1=C(CSC2=NN=NN2C)CS[C@]([H])([C@@H]3NC(/C(C4=CSC(N)=N4)=N\OC)=O)N1C3=O)=O.Cl |
靶点 |
Bacterial |
通路 |
Anti-infection |
背景说明 |
是第三代头孢类抗生素。 |
生物活性 |
Cefmenoxime (SCE-1365) hydrochloride is a new semisynthetic cephalosporin antibiotic. Cefmenoxime has antibacterial activity against a wide variety of gram-positive and gram-negative bacteria[1][2]. |
IC50 |
β-lactam |
In Vitro |
Cefmenoxime (SCE-1365) hydrochloride inhibits at least 90% of strains tested (MIC90) ranged from 0.06 to 8 μg/mL for the Enterobacteriaceae[1].Cefmenoxime (SCE-1365) hydrochloride inhibits MIC90 values for gram-positive cocci are 0.015 and ≤0.008 μg/mL for Streptococcus pneumoniae and Streptococcus pyogenes, respectively, and 2 μg/mL for S. aureus[1].Cefmenoxime (SCE-1365) hydrochloride against Haemophilus influenzae, Neisseria gonorrhoeae, and Neisseria meningitidis with MIC90 values ranging from ≤0.008 to 0.25 μg/mL[1]. |
In Vivo |
Cefmenoxime (SCE-1365) hydrochloride (40 mg/kg; i.h.; daily, for 7 d; male Jcl:ICR mice) improves the survival rate of mice infected with lung bacteria[2]. |
数据来源文献 |
[1]. Stamm JM, et, al. Antimicrobial activity of cefmenoxime (SCE-1365). Antimicrob Agents Chemother. 1981 Mar;19(3):454-60. [2]. Tatara O, et, al. Synergistic effects of romurtide and cefmenoxime against experimental Klebsiella pneumonia in mice. Antimicrob Agents Chemother. 1992 Jan;36(1):167-71. |
规格 |
25mg 50mg 100mg 500mg 1g |
单位 |
瓶 |